Navigation Links
Adeona Reports Third Quarter 2011 Financial Results
Date:11/14/2011

ANN ARBOR, Mich., Nov. 14, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its third quarter 2011 financial results for the period ended September 30, 2011, as well as updates since the beginning of the third quarter.

Updates since the beginning of the third quarter include:

Drug Development Programs

Relapsing-Remitting Multiple Sclerosis (MS)

  • As of September 19, 2011, the 150th patient was enrolled in the clinical trial evaluating Trimesta™ (oral estriol) in women suffering from relapsing-remitting MS, per the original protocol.

  • The Lead Principal Investigator, Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, Department of Neurology, is using grant funding to continue enrollment of an additional 10-20 patients at all 15 centers in the United States.

Cognitive Dysfunction in MS

  • On November 11, 2011, we announced that our drug candidate, Trimesta, will be utilized in a new randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction in women suffering from MS, a major consequence of this disease.

  • We and the Skirball Foundation have pledged to equally support this clinical trial led by Dr. Voskuhl. The study, which focuses on cognition dysfunction in MS patients, also received financial support from the Sherak Family Fund, the Gustafson Fund, and the Diamont family.

Fibromyalgia

  • In May 2010, we announced a $17.5 million c
    '/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
2. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
3. Adeona Appoints Jeff Lucero Riley as Independent Chairman
4. Adeonas Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease is Hot Topic at 2011 California ALS Research Summit
5. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
6. Adeona Appoints George A. Eby to Scientific Advisory Board
7. Adeona Reports Second Quarter 2011 Financial Results
8. Adeona to Host Second Quarter 2011 Investor Conference Call
9. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
10. Adeona Reports 1st Quarter 2011 Financial Results
11. Adeona to Host First Quarter 2011 Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 2011 Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies -- today announced that Dr. Claire Kruger, Chief ... presenting a corporate overview at the Rodman & Renshaw ...
... Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals ... Executive Officer, will present at the Rodman and Renshaw ... 2:25pm ET at the Waldorf Astoria Hotel in New ... Founded in 2008, Omthera Pharmaceuticals, Inc. ...
Cached Medicine Technology:Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... SILVER SPRING, Md., Dec. 24 The American Nurses Association (ANA), ... for passing H.R. 3590, " The Patient Protection and Affordable ... vote of 60-39. ANA had urged passage of the legislation and ... members of Congress, was read on the Senate floor by Majority ...
... , , WASHINGTON, Dec. 24 ... Senate voted to pass the Patient Protection and Affordable Care ... bill on Christmas Eve, after overcoming a series of procedural ... stop the bill from ever reaching the Senate floor for ...
... Dec. 24 The American ... of legislation that holds the promise of more comprehensive coverage ... those without. , We are pleased that the ... our association,s principles for comprehensive health reform, and that the ...
... 24 The following statement is attributable to J. James ... Senate took an historic vote to improve our nation,s health ... strengthening the private insurance market to better serve the patients ... the bill because it contains a number of key improvements ...
... well-tolerated, researchers say , WEDNESDAY, Dec. 23 (HealthDay News) -- ... an effective treatment for Ewing,s sarcoma, a cancer that affects ... boys. , The drug must undergo two more phases of ... 23 online edition of The Lancet Oncology . , ...
... before proposal can become law , THURSDAY, Dec. 24 (HealthDay ... Eve gift on Thursday with passage of a landmark health ... Americans. , Obama said the Senate bill contains 95 percent ... inauguration on Jan. 20. "Every single criteria for reform that ...
Cached Medicine News:Health News:Senate Passes Landmark Health Care Reform Bill 2Health News:DNC Chairman Tim Kaine Calls Senate Vote Historic, Says Landmark Health Reform Bill Is a Victory for the American People 2Health News:APA Statement on Senate Passage of Health Care Reform Legislation 2Health News:AMA: Senate Bill Passage Historic, More Work to Do in Conference 2Health News:Senate Passes Health Reform Package 2Health News:Senate Passes Health Reform Package 3Health News:Senate Passes Health Reform Package 4
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... protection' -- providing complete protection from initial ... with side branches. , ,Proxis is ... not require the attachment or exchange of ... ,Proxis is compatible with all standard ...
... electrophysiology system on the market today, the ... patented "C inside a C" design offering ... ultimate in patient access and flexibility. Usable ... minimizes equipment footprint and can be parked ...
Medicine Products: